###begin article-title 0
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
Evidence for a Pathogenic Role of Different Mutations at Codon 188 of PRNP
###end article-title 0
###begin p 1
Conceived and designed the experiments: CV HK IZ SR EG OW. Performed the experiments: TI CV SR EG OW BK WX AS TA PW. Analyzed the data: TI CV HK IZ SR EG OW BK WX AS TA PW. Contributed reagents/materials/analysis tools: TI CV IZ SR EG OW BK WX PW. Wrote the paper: SR EG OW. Other: Revised the article critically for important intellectual content and approved the final version for publication: HK.
###end p 1
###begin p 2
Current address: Molecular Pathogenesis and Genetics Department, Veterinary Laboratories Agency-Weybridge, New Haw, Addlestone, Surrey, United Kingdom
###end p 2
###begin p 3
###xml 185 189 185 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
Clinical and pathological changes in familial Creutzfeldt-Jakob disease (CJD) cases may be similar or indistinguishable from sporadic CJD. Therefore determination of novel mutations in PRNP remains of major importance.
###end p 3
###begin p 4
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP)</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 373 380 <span type="species:ncbi:9606">patient</span>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 747 754 <span type="species:ncbi:9606">patient</span>
We identified two different rare mutations in codon 188 of the prion protein gene (PRNP) in four patients suffering from a disease clinically very similar to the major subtype of sporadic CJD. Both mutations result in an exchange of the amino acid residue threonine for a highly basic residue, either arginine (T188R) or lysine (T188K). The T188R mutation was found in one patient and the T188K mutation in three patients. The prevalence of mutations at codon 188 of PRNP was tested in 593 sporadic CJD cases and 735 healthy individuals. Neither mutation was found. The data presented here argue in favor of T188K being a pathogenic mutation causing genetic CJD. Since one individual with this mutation, who is the father of a clinically affected patient with T188K mutation, is now 79 years old and shows no signs of disease, this mutation is likely associated with a penetrance under 100%. Further observations will have to show whether T188R is a pathogenic mutation.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 342 346 342 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 363 366 363 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Goldfarb1">[1]</xref>
###xml 368 371 368 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl1">[2]</xref>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 191 196 <span type="species:ncbi:9606">human</span>
###xml 316 321 <span type="species:ncbi:9606">human</span>
Human prion diseases can be idiopathic, acquired or genetic. The majority of cases are idiopathic and are generally referred to as sporadic Creutzfeldt-Jakob disease (sCJD). About 10%-15% of human prion diseases are inherited in an autosomal, dominant fashion and in all cases a mutation in the coding region of the human prion protein gene (PRNP) has been found [1], [2]. Depending on their clinical and pathological phenotypes, the inherited prion diseases have been termed as genetic (familial) CJD, Gerstmann-Straussler-Scheinker syndrome (GSS) or fatal familial insomnia (FFI). More than 20 different point mutations are known to date which are found to be associated or genetically linked with inherited prion diseases. These point mutations cluster in the central and in the more C-terminal part of the prion protein (PrP) encoded by PRNP.
###end p 6
###begin p 7
###xml 401 404 401 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Goldgaber1">[3]</xref>
###xml 405 408 405 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Medori1">[7]</xref>
###xml 573 576 573 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Kovacs1">[4]</xref>
###xml 645 649 645 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 759 763 759 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 39 44 <span type="species:ncbi:9606">human</span>
The most common mutations in inherited human prion diseases are well described and their phenotypic range has been determined. The glutamate to lysine mutation at codon 200 (E200K) is causative of the majority of familial CJD cases, the proline to leucine mutation at codon 102 (P102L) for GSS and the aspartate to asparagine mutation at codon 178 (D178N) coupled with methionine at codon 129 for FFI [3]-[7]. Whereas the clinical and histopathological spectrum of GSS and FFI differ from sCJD, the spectrum of familial CJD overlaps in many cases with the spectrum of sCJD [4] . In the absence of genetic testing of suspected sCJD, mutations of PRNP often would not be detected and familial CJD would be underreported. The determination of novel mutations in PRNP remains of major importance for the following reasons. (1) The identification of new mutations might identify some dementing or neurodegenerative clinical syndromes as prion diseases, thus expanding the spectrum of prion diseases and improving the differential diagnosis during lifetime. (2) Every novel mutation adds valuable insights to our understanding as to how such changes in PrP cause prion diseases. (3) Several mutations giving rise to a phenotype mimicking sCJD may have been overlooked due to an examination bias towards known mutations. This may lead to erroneous diagnoses with implications for the affected families.
###end p 7
###begin p 8
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
Here we report two different rare mutations at codon 188 of PRNP in four cases of clinically diagnosed and one autopsy proven CJD case and argue that mutations at this position are causative of genetic CJD. The mutations are located in a highly conserved region and alter the codon 188 from threonine (T) to a basic amino acid residue, either arginine (T188R) or lysine (T188K).
###end p 8
###begin title 9
Materials and Methods
###end title 9
###begin title 10
Clinical history/Neuropathology
###end title 10
###begin p 11
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl2">[5]</xref>
###xml 187 190 187 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Mollenhauer1">[8]</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">Patients</span>
###xml 229 236 <span type="species:ncbi:9606">patient</span>
###xml 312 319 <span type="species:ncbi:9606">patient</span>
Patients A-D were identified as part of the German CJD surveillance program, where about 2000 patients were investigated clinically, genetically and many of them neuropathologically [5], [8]. Patients A-C were not autopsied. For patient D informed consent for autopsy was received from parents. The relatives of patient D (sister (E), father (F), mother (G)) were clinically inconspicuous and received predictive genetic analysis after signed informed consent.
###end p 11
###begin p 12
###xml 780 783 766 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Kahle1">[9]</xref>
###xml 969 973 951 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-SchulzSchaeffer1">[10]</xref>
###xml 29 36 <span type="species:ncbi:9606">patient</span>
One year before the death of patient D we received a 3-mm tissue sample from a brain biopsy, after her death a brain autopsy was performed. The left hemisphere was fixed in formalin and the right hemisphere was frozen (-80degreesC). Histological examination was performed on 4 microm thick sections of 17 regions of formalin-fixed and paraffin embedded cerebrum, cerebellum and brainstem. Hematoxylin and eosin (H&E) as well as Gallyas silver stain, Luxol fast blue-periodic acid Schiff (LFB-PAS) and Bielschowsky stains were performed using standard techniques. Immunohistochemistry was performed with antibodies directed against PrP (L42, 1:100, gift from M. Groschup), phosphorylated tau (AT8, 1:200, Innogenetics, Ghent, Belgium), alpha-synuclein (15G7, 1:10, own production, [9]) and alphaB-crystalline (1:500, Calbiochem, Nottingham, UK). Paraffin-embedded tissue (PET) blotting was performed using the antibody 12F10 (gift from J. Grassi) as described elsewhere [10].
###end p 12
###begin title 13
Genetic analysis
###end title 13
###begin p 14
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 491 494 491 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl2">[5]</xref>
For genetic analysis DNA was extracted from blood lymphocytes or from frozen post-mortem brain tissue according to standard procedures. The coding region of PRNP was amplified by the polymerase chain reaction (PCR) and first subjected to single-stranded conformational polymorphism (SSCP) analysis. In case a mutation was indicated, the complete open reading frame of PRNP was analyzed by direct sequencing of PCR products using the automated LICOR 4200 DNA analyzer as described previously [5].
###end p 14
###begin p 15
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Palmer1">[11]</xref>
###xml 438 442 438 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 496 499 496 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl2">[5]</xref>
###xml 16 23 <span type="species:ncbi:9606">patient</span>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 104 111 <span type="species:ncbi:9606">persons</span>
###xml 183 190 <span type="species:ncbi:9606">patient</span>
The mutation in patient A was detected by the procedure as described. The mutations in patients B-D and persons E-G were detected by direct sequencing without prior SSCP analysis. In patient C a silent mutation at codon 117 complicated the analysis due to a polymorphism co-migrating in the region of the 5'-primer leading to preferential amplification of the allele with the silent mutation [11]. The re-analysis of the coding region of PRNP by PCR was then performed with a different 5'-primer [5].
###end p 15
###begin p 16
###xml 136 139 136 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl3">[12]</xref>
###xml 170 173 170 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xma</italic>
The amino acid at codon 129 in coupling with the mutation was determined by cloning. For this purpose, the PCR product was cleaved with EcoRI (part of primer B [12]) and XmaI (at codon 40 of the prion protein), the large fragment was purified and cloned into the appropriate cleavage sites of pBluescriptIIKS(-) (Stratagene, La Jolla, CA). The mutation and the respective codon 129 were verified by sequencing of three independent clones.
###end p 16
###begin title 17
Single nucleotide polymorphism (SNP) analysis
###end title 17
###begin p 18
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Vollmert1">[13]</xref>
###xml 350 352 350 352 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ko</underline>
###xml 386 387 386 387 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</underline>
###xml 391 392 391 392 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</underline>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Wichmann1">[14]</xref>
###xml 547 551 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Holle1">[15]</xref>
###xml 563 575 <span type="species:ncbi:9606">participants</span>
The prevalence of mutations at codon 188 of PRNP was tested in a sCJD cohort (593 sCJD cases; 387 "definite" and 206 "probable" sCJD), received from a large German study on the genetics of prion diseases, and 735 healthy individuals [13]. The latter were taken from a population-based German study performed in the city and region of Augsburg (KORA; Kooperative Gesundheitsforschung im Raum Augsburg, Survey 4, 2000), which is a representative sample of the adult general population of German nationality and were matched for age and gender [14], [15]. All study participants gave informed written consent according to the Bavarian Ethics committee and the Ethics committee of the Ludwig-Maximilians-University of Munich.
###end p 18
###begin p 19
###xml 171 172 171 172 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</underline>
###xml 178 179 178 179 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</underline>
###xml 187 188 187 188 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</underline>
###xml 193 194 193 194 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</underline>
###xml 204 205 204 205 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</underline>
###xml 215 216 215 216 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</underline>
###xml 220 221 220 221 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">o</underline>
###xml 223 224 223 224 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</underline>
###xml 230 231 230 231 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</underline>
###xml 235 236 235 236 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">s</underline>
###xml 400 436 391 427 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">3&#8242;-ACGTTGGATGTCATCTTAACGTCGGTCTCG-5&#8242;</named-content>
###xml 441 477 432 468 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">3&#8242;-ACGTTGGATGCACGACTGCGTCAATATCAC-5&#8242;</named-content>
###xml 737 761 719 743 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">3&#8242;-TTGGTGGTTGTGGTGACC-5&#8242;</named-content>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Genomic DNA of sCJD patients was extracted from blood lymphocytes according to standard procedures. The SNP analysis for both mutations (T188R, T188K) was performed using matrix assisted laser desorption/ionisation time of flight mass spectrometry (MALDI-TOF MS, Mass Arraytrade mark, Sequenom, San Diego, CA, USA). Briefly, genomic DNA of each subject was tested individually using PCR with primers 3'-ACGTTGGATGTCATCTTAACGTCGGTCTCG-5' and 3'-ACGTTGGATGCACGACTGCGTCAATATCAC-5' generating products of 108 bp. Following purification of the PCR products homogenous MassEXTEND reactions (hMEtrade mark, Sequenom, San Diego, CA, USA) were performed by adding a mixture of dideoxy and deoxynucleotides and the test-specific MassEXTEND primer 3'-TTGGTGGTTGTGGTGACC-5', which is complementary to the template at a region directly adjacent to the polymorphic site. The hME products were spotted onto a 384 SpectroCHIP microarray for fully automated mass spectrometry analysis (Biflex mass spectrometer, Bruker Daltonik GmbH, Bremen, Germany; MassArraytrade mark, Sequenom, San Diego, CA, USA).
###end p 19
###begin title 20
Western Blot
###end title 20
###begin p 21
###xml 390 394 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Notari1">[16]</xref>
###xml 60 67 <span type="species:ncbi:9606">patient</span>
For Western blot analysis tissue from the frontal cortex of patient D was homogenised in 9 volumes (wt/vol) of lysis buffer (0.5% Nonidet P-40, 0.5% DOC, 10 mM EDTA, 100 mM NaCl, 100 mM Tris, pH 6.9 at 37degreesC). After PK digestion (100 microg/ml, 1h at 37degreesC) cleared homogenates were subjected to SDS-PAGE (12% NuPage, Invitrogen, Karlsruhe, Germany) and blotted on PVDF-membranes [16]. For comparison we used brain homogenates from two sCJD cases (MM1 and VV2). The monoclonal anti-PrP antibody 3F4 (1:3000, DAKO), recognizing the epitope 109-112 of PrP, was used for immunodetection. Protease-resistant PrP was visualized by enhanced chemiluminescence reaction (GE Healthcare, Freiburg, Germany).
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
Clinical history
###end title 23
###begin title 24
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient A
###end title 24
###begin p 25
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Zerr1">[17]</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 403 410 <span type="species:ncbi:9606">patient</span>
###xml 436 442 <span type="species:ncbi:9606">person</span>
###xml 1367 1374 <span type="species:ncbi:9606">patient</span>
###xml 1511 1518 <span type="species:ncbi:9606">patient</span>
The patient was of Caucasian descent, born and raised in Germany. She spent the last 33 years of her life in Indonesia. At age 66 she presented with progressive visual impairment followed several months later by progressive dementia and slight ataxia. Her medical history was unremarkable aside from a malaria episode. On examination during a visit in Germany, 12 months after onset of the disease, the patient was oriented towards her person, but disoriented in time. She had impaired short-term memory and reported increased exhaustion, tiredness and weight loss. Examination of her CSF revealed neuron-specific enolase (NSE) of 38 ng/ml (cut-off 35 ng/ml for an optimum sensitivity and specificity for the diagnosis of CJD [17]), intrathecal IgG-production and 14-3-3 proteins. In the cerebral magnetic resonance imaging (MRI) 12 months after onset only one small (7 mm) lesion was found in the frontal white matter on both sides. They were hyperintense on T2, invisible on T1, non-enhancing and interpreted as "myelinoclastic lesions". The electroencephalogram (EEG) showed typical periodic sharp-wave complexes (PSWCs). The sensory evoked potentials (SEP) and acoustical evoked potentials (AEP) were normal, the monocular visual evoked potentials (VEP) indicated a demyelinating lesion on both sides, most likely localized in the prechiasmatic optic nerves. The patient died 16 months after the onset of her disease. An autopsy was not performed. A family history of dementing illnesses was not known. The patient's father had succumbed to pleuritis at a very young age (31 y).
###end p 25
###begin title 26
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient B
###end title 26
###begin p 27
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 374 381 <span type="species:ncbi:9606">patient</span>
###xml 1165 1172 <span type="species:ncbi:9606">patient</span>
###xml 1312 1319 <span type="species:ncbi:9606">patient</span>
###xml 1414 1421 <span type="species:ncbi:9606">patient</span>
###xml 1508 1515 <span type="species:ncbi:9606">patient</span>
The patient was born in Germany and lived there for her whole life. At age 76 she presented with coordination problems of the left hand and slight disturbances of her gait. Involuntary movements, alien limb-sign, focal dystonia, rigor of upper extremities, apraxia and ataxia were found. In a first Mini Mental State Examination (MMSE) test three months after the onset the patient scored normal. The initial diagnosis was corticobasal degeneration. Only one month later she was severely demented. She developed visual problems, up-beat nystagmus and dysarthria. In the CSF the NSE level was 28 ng/ml (elevated, but below the cut-off of 35 ng/ml for CJD diagnosis) and the Western blot for 14-3-3 was positive. The initial MRI, two months after onset, showed moderate atrophy of the fronto-parietal cortex and little unspecific white matter lesions fronto-parietal. The MRI one month prior death revealed an abnormal T2 signal in the basal ganglia on both sides. The single-photon emission computed tomography (SPECT) revealed a hypoperfusion of the parietal cortex bilaterally. The EEG showed PSWCs. The VEP revealed a delay of the P100 component bilaterally. The patient died 5 months after the onset of the disease and was not autopsied. At that time, the younger sister (59 y) was healthy. The mother of the patient was reported having died aged 64 from a rapidly progressing dementia. Yet, the parents of the patient's mother died late in life (74 y and 89 y) of non-dementing disorders. The son of the patient died from an unknown liver disease at the age of 51 y.
###end p 27
###begin title 28
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient C
###end title 28
###begin p 29
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 88 95 <span type="species:ncbi:9606">patient</span>
###xml 770 777 <span type="species:ncbi:9606">patient</span>
###xml 923 930 <span type="species:ncbi:9606">patient</span>
The patient was born and lived for her whole life in Germany within 140 kilometres from patient B. At age 69 she presented with vertigo, personality changes and visual disturbances followed soon after by involuntary movements of the left limbs and a hemiparesis of the left side. Short-term memory was impaired and myoclonus was present. Signs of ataxia were diagnosed on neurological examination three months after onset. The cerebral MRI two and three months after onset showed mild enlargement of the ventricular spaces and periventricular unspecific white matter lesions in the centrum semiovale. PSWCs were indicated in the EEG. The examination of CSF revealed 14-3-3 proteins and a clearly elevated NSE level of 140 ng/ml (cut-off 35 ng/ml for CJD diagnosis). The patient's condition deteriorated rapidly and she was bed-ridden with akinetic mutism four months after the onset of the disease. Three months later, the patient died and no autopsy was performed. No family history of a dementing disease was known, both her parents died of unrelated diseases aged 77 and 87 years.
###end p 29
###begin title 30
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient D
###end title 30
###begin p 31
###xml 678 682 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-WHO1">[18]</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 75 82 <span type="species:ncbi:9606">patient</span>
###xml 108 115 <span type="species:ncbi:9606">patient</span>
###xml 165 170 <span type="species:ncbi:9606">woman</span>
The patient lived for her whole life in Germany within 130 kilometres from patient B and 10 kilometres from patient C. One year preceding her death this 58 year old woman subacutely developed dizziness, aphasia, alexia, apraxia and dysdiadochokinesia of the right hand. The symptoms were clearly progressive during the next two weeks. The MRI, one month after onset, showed cortical signal enhancement of the left temporal lobe. The EEG showed no regular activity with intermittent bilateral PSWCs. Elevated tau protein (2218 pg/ml) and 14-3-3 proteins were detectable in the CSF. According to the criteria for clinical diagnosis of CJD the diagnosis of "probable CJD" was made [18]. During the following weeks the disease progressed to a condition of mutism, the muscle tone increased and myoclonic jerks appeared. She died one year after the onset of clinical signs in a nursing home. No similar diseases were reported in her family.
###end p 31
###begin title 32
Genetics
###end title 32
###begin title 33
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient A
###end title 33
###begin p 34
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 400 409 400 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g001">Figure 1B</xref>
###xml 121 129 <span type="species:ncbi:9606">patients</span>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
The analysis of the coding region of PRNP showed an abnormal pattern in the SSCP analysis compared to the normal PRNP of patients without sequence aberrations and to PRNP of patients with various known mutations. Sequencing revealed a cytosine to guanine transversion at the second position at codon 188 on one allele resulting in an amino acid exchange of threonine (ACG) to arginine (AGG) (T188R) (Figure 1B). The amino acid at codon 129 was valine (V) at both alleles.
###end p 34
###begin title 35
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Sequence analysis of PRNP in three patients with prion diseases.
###end title 35
###begin p 36
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 159 166 <span type="species:ncbi:9606">patient</span>
###xml 198 205 <span type="species:ncbi:9606">patient</span>
###xml 240 247 <span type="species:ncbi:9606">patient</span>
The coding region was sequenced using fluorescence-labeled primers on an automated sequencing system (LI-COR, Lincoln, Neb.). Short fragments of PRNP of (A) a patient with the normal codon 188, (B) patient A with the T188R mutation and (C) patient B with the T188K mutation are shown using a primer for the sequencing that reads the antisense strand.
###end p 36
###begin title 37
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 19 26 <span type="species:ncbi:9606">persons</span>
Patients B,C,D and persons E,F,G
###end title 37
###begin p 38
###xml 198 207 198 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g001">Figure 1C</xref>
###xml 599 603 599 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 1049 1053 1049 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 30 37 <span type="species:ncbi:9606">persons</span>
###xml 185 192 <span type="species:ncbi:9606">persons</span>
###xml 299 306 <span type="species:ncbi:9606">patient</span>
###xml 516 523 <span type="species:ncbi:9606">patient</span>
###xml 677 684 <span type="species:ncbi:9606">persons</span>
###xml 881 887 <span type="species:ncbi:9606">Person</span>
###xml 955 962 <span type="species:ncbi:9606">patient</span>
###xml 1012 1019 <span type="species:ncbi:9606">patient</span>
###xml 1023 1029 <span type="species:ncbi:9606">person</span>
Samples of patients B,C,D and persons E,F,G were directly sequenced after PCR amplification. A transversion to adenine at the second position at codon 188 on one allele was observed in persons B-F (Figure 1C). The resulting amino acid exchange was threonine to lysine (AAG) (T188K). The mutation in patient C was clearly visible only after re-analysis with a different PCR-primer due to a polymorphism in the primer-binding region of the gene that is co-migrating with the silent mutation at codon 117. In fact, the patient C turned out to be heterozygous at three positions in the coding region of PRNP: the silent polymorphism at codon 117 and the codons 129 and 188. As the persons B, C, D, E were heterozygous (methionine (M)/V) at the polymorphic codon 129, the amino acid at this position in coupling with lysine at 188 was determined as M in all cases by molecular cloning. Person F was homozygous at codon 129 for M. The codon 117 polymorphism in patient C was coupled with V at codon 129. The mother of patient D (person G) did not carry a PRNP mutation.
###end p 38
###begin title 39
SNP screening
###end title 39
###begin p 40
###xml 318 325 <span type="species:ncbi:9606">persons</span>
In order to test the prevalence of the T188R and the T188K mutations in sporadic CJD and in the healthy population a big study cohort consisting of 593 sCJD cases and 735 healthy individuals was screened. The mutations T188R and T188K or different nucleotide changes at codon 188 were not found in any of the examined persons.
###end p 40
###begin title 41
###xml 31 42 31 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(Patient D)</italic>
###xml 32 39 <span type="species:ncbi:9606">Patient</span>
Histology/Immunohistochemistry (Patient D)
###end title 41
###begin p 42
###xml 181 186 <span type="species:ncbi:9606">human</span>
The histological examination of the tissue received from biopsy showed parts of the neocortex with spongiform changes and gliosis. Immunohistochemistry with an antibody against the human prion protein (PrP) (L42) revealed synaptic staining of the cortex.
###end p 42
###begin p 43
###xml 550 559 550 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g002">Figure 2A</xref>
###xml 669 678 669 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g002">Figure 2B</xref>
###xml 1151 1152 1147 1148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</italic>
###xml 1152 1161 1148 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g002">Figure 2A</xref>
###xml 1476 1485 1472 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g002">Figure 2C</xref>
###xml 1896 1907 1892 1903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g002">Figure 2D,F</xref>
###xml 2064 2073 2060 2069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g002">Figure 2E</xref>
###xml 1777 1782 <span type="species:ncbi:9606">human</span>
The neuropathological gross examination of the brain showed a moderate frontal atrophy, a diminution of cortical thickness in all regions, enlarged ventricles and a thin corpus callosum. The cerebellum revealed atrophy, especially of the superior lobe. The brainstem was macroscopically unaffected. The cerebral vessels showed mild arteriosclerotic changes. Histological examination of HE stained sections revealed severe spongiform changes in all layers of the cerebral cortex, astrocytic gliosis and neuronal depletion increasing from the frontal (Figure 2A) to the occipital lobe. Status spongiosus was found in the entorhinal, transentorhinal and occipital cortex (Figure 2B), putamen and caudate nucleus. The globus pallidus and cornu Ammonis showed only minor spongiform changes, which was more pronounced in the subiculum and amygdala. The medial and lateral part of the thalamus showed severe spongiform changes, astrocytic gliosis and neuronal loss. The nucleus basalis of Meynert revealed moderate gliosis. Furthermore numerous alphaB-crystalline immunoreactive ballooned neurons were found in the cortex of the cingulate gyrus, the frontal (Figure 2A insert) and temporal lobe and a small number in the external layer of entorhinal cortex. Mild demyelination and axonal loss were found mainly in the occipital lobe. The cerebellar cortex showed moderate spongiform changes of the molecular layer, severe degeneration of the granular cell layer with some torpedoes (Figure 2C). The Purkinje cells were mainly preserved. Moderate atrophy of cerebellar white matter was noted. The brainstem was nearly free of spongiform change, but astrocytic gliosis was found mainly in pons and the tegmentum of the whole brainstem. Immunohistochemistry with an antibody against the human prion protein (PrP) (L42) revealed strong synaptic staining of all layers of the cerebral and cerebellar cortex (Figure 2D,F), the hippocampus, the amygdala, the basal ganglia, the thalamus, the dentate nucleus, grey matter of the brainstem and the plexiform layers of the retina (Figure 2E). The PET blot of the hippocampus and cerebellar cortex showed intensive synaptic staining. The immunostaining with an antibody against hyperphosphorylated tau protein (AT8) revealed a few neurofibrillary tangles and neuropil threads in the transentorhinal cortex, the external and internal layer of the entorhinal cortex and few in the CA1 region and amygdala. These were not detectable using the Gallyas silver stain.
###end p 43
###begin title 44
###xml 42 49 <span type="species:ncbi:9606">Patient</span>
Post-mortem neuropathological findings in Patient D.
###end title 44
###begin p 45
###xml 489 491 485 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
A: Spongiform changes in the frontal cortex with numerous ballooned neurons (H&E, original magnification 100x); Inserts: Immunohistochemistry of ballooned neurons (alphaB-Crystalline; 20x and 200x). B: Status spongiosus in the occipital cortex (H&E, 100x). C: Cerebellar cortex with moderate spongiform changes of the molecular layer and severe degeneration of the granular cell layer (H&E, 20x). D-F: Immunohistochemistry with an antibody against PrP (L42) shows a synaptic pattern of PrPSc deposition. D: Frontal cortex (40x), E: Retina (400x). F: Cerebellar cortex (20x).
###end p 45
###begin title 46
###xml 23 33 23 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Patient D)</italic>
###xml 23 30 <span type="species:ncbi:9606">Patient</span>
Western blot analysis (Patient D)
###end title 46
###begin p 47
###xml 134 136 134 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 163 171 163 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g003">Figure 3</xref>
###xml 230 238 230 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002147-g003">Figure 3</xref>
###xml 443 447 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Tagliavini1">[19]</xref>
###xml 448 452 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Satoh1">[22]</xref>
###xml 52 59 <span type="species:ncbi:9606">patient</span>
The protease resistant PrP in brain homogenate from patient D was further analysed using Western blotting with the antibody 3F4. A PrPSc pattern type 1 was found (Figure 3, lane 3) similar to the type 1 pattern of sCJD case (MM1, Figure 3, lane 1). In addition there was a fragment migrating at about 17 kDa detected with the antibody 3F4. Additional bands have been reported in genetic prion diseases (mainly GSS), some also in sCJD and iCJD [19]-[22].
###end p 47
###begin title 48
Western blot analysis of PrP after proteinase K digestion (lanes 1-3) using mAb 3F4.
###end title 48
###begin p 49
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lane1:</italic>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lane 2</italic>
###xml 57 59 57 59 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lane 3</italic>
###xml 119 126 <span type="species:ncbi:9606">patient</span>
Lane1: PrPSc type 1 from a sporadic CJD case. Lane 2: PrPSc type 2 from a sporadic CJD case. Lane 3: Frontal cortex of patient D. As seen in lane 3 there is an additional band migrating at an apparent MW of 17 kDa.
###end p 49
###begin title 50
Discussion
###end title 50
###begin p 51
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 133 140 133 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002147-t001">Table 1</xref>
###xml 635 638 635 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl2">[5]</xref>
###xml 640 644 640 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Kovacs2">[23]</xref>
###xml 666 670 666 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Finckh1">[24]</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Collins1">[25]</xref>
###xml 21 29 <span type="species:ncbi:9606">patients</span>
###xml 232 237 <span type="species:ncbi:9606">human</span>
###xml 271 279 <span type="species:ncbi:9606">Patients</span>
###xml 428 435 <span type="species:ncbi:9606">Persons</span>
###xml 470 477 <span type="species:ncbi:9606">Patient</span>
###xml 582 589 <span type="species:ncbi:9606">Patient</span>
###xml 700 707 <span type="species:ncbi:9606">patient</span>
###xml 851 858 <span type="species:ncbi:9606">patient</span>
Here we present four patients carrying two different mutations at codon 188 of PRNP - T188K and T188R (for a summary of findings see Table 1). We show immunohistochemical data confirming that the T188K mutation is associated with a human prion disease (CJD) in one case. Patients B, C and D are from the same circumscribed region in Germany and were born not more than 140 km from each other; no familial relationship is known. Persons E and F, the sister and father of Patient D, have a T188K mutation and are healthy at ages 51 and 79 years respectively. The case with the T188R (Patient A) mutation is the only one reported to date [5], [23]. A T188K mutation of PRNP was published in an Austrian patient with rapid progressive dementia [24]. There is no histological description of these two cases. A T188A mutation was described in an Australian patient [25].
###end p 51
###begin title 52
Features of the prion diseases associated with mutations at codon 188. Abbreviations: AA = amino acid; n.a. = not available, IHC = Immunohistochemistry; m. = month; M = methionine; V = valine; y. = years.
###end title 52
###begin p 53
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 100 107 <span type="species:ncbi:9606">patient</span>
A comparison of the four cases with the T188K mutation (patients B-D of this study and the Austrian patient) shows a heterogeneous clinical picture concerning age at onset (57-76 y), disease duration (5-13 m), symptoms at onset (ataxia, personality change and aphasia) and MRI findings (Table1).
###end p 53
###begin p 54
###xml 380 387 380 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002147-t001">Table 1</xref>
###xml 389 393 389 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-WHO1">[18]</xref>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-WHO2">[26]</xref>
###xml 523 527 523 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 571 575 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 616 618 616 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 754 758 754 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Parchi2">[27]</xref>
###xml 195 202 <span type="species:ncbi:9606">patient</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 404 411 <span type="species:ncbi:9606">patient</span>
###xml 599 606 <span type="species:ncbi:9606">patient</span>
The cases B, C and D were originally classified as "probable sCJD" according to the diagnostic criteria for sCJD established by the WHO-guidelines as they showed the obligatory criteria and two (patient B) or all four (patients C and D) of the following clinical features: myoclonus, visual or cerebellar disturbances, pyramidal or extrapyramidal disturbances or akinetic mutism (Table 1) [18], [26]. In patient D a diagnosis of "definite CJD" was made after death. The genetic analysis revealed a mutation at codon 188 of PRNP (T188K) and heterozygosity at codon 129 of PRNP in the three cases. In patient D the PrPSc type 1 was found in the Western blot analysis (Parchi et al.1999) and the histological picture was indistinguishable from sCJD-MM1/MV1 [27], except for the numerous ballooned neurons in the cortex, which are not seen in sCJD-MM1.
###end p 54
###begin p 55
###xml 12 16 12 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 261 265 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Jin1">[28]</xref>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Nitrini1">[29]</xref>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Krasnianski1">[30]</xref>
###xml 482 486 482 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Meissner1">[31]</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Tschampa1">[32]</xref>
###xml 1043 1047 1043 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-WHO2">[26]</xref>
###xml 1049 1053 1049 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Young1">[33]</xref>
###xml 1055 1059 1055 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Cambier1">[34]</xref>
###xml 661 668 <span type="species:ncbi:9606">patient</span>
###xml 836 843 <span type="species:ncbi:9606">patient</span>
###xml 940 947 <span type="species:ncbi:9606">patient</span>
A number of PRNP mutations are associated with characteristic cerebral MRI findings. A signal hyperintensity in the cerebral cortex more than in the basal ganglia (BG) was recognized as a characteristic feature in genetic CJD with the PRNP codon V180I mutation [28]. Mutations in codon 183 and 210 show abnormalities in the BG and cerebral cortex similar to sCJD [29]. Recent studies revealed that particular sCJD subtypes (MV2, VV1) also show specific characteristics on MRI [30], [31]. In the three cases with the T188K mutation no characteristic cerebral MRI pattern was identified. The typical T2 signal in the BG as proposed for sCJD criteria was found in patient B only [32]. In addition a hypoperfusion of the parietal cortex bilaterally was found in SPECT, but not on T2 weighted MRI 2-4 months after onset. The MRI findings in patient C were uncharacteristic. The isolated cortical hyperintensity on MRI and the missing BG sign in patient D may be due to the early time point when the single MRI was performed (one month after onset) [26], [33], [34].
###end p 55
###begin p 56
###xml 198 201 198 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Kovacs1">[4]</xref>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl3">[12]</xref>
###xml 454 458 454 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Pocchiari1">[35]</xref>
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Goldfarb2">[38]</xref>
###xml 554 560 <span type="species:ncbi:9606">Person</span>
Absence of a positive family history is noted in a significant proportion of genetic CJD cases (5-88%, depending on the mutation) and has drawn the attention to the issue of penetrance of mutations [4], [12]. Our findings suggest that the T188K mutation may not be fully penetrant as controversially discussed for other mutations (E200K, V210I) causing clinical phenotypes very similar to sCJD or that the pathogenic effect depends on additional factors [35]-[38]. Such factors could be the codon 129 polymorphism; whether this is of any significance in Person F, who is clinically not affected at age 79 and homozygous for M, is unknown at present.
###end p 56
###begin p 57
###xml 128 131 128 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl2">[5]</xref>
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Kovacs2">[23]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Spiegel1">[39]</xref>
###xml 35 42 <span type="species:ncbi:9606">patient</span>
###xml 491 499 <span type="species:ncbi:9606">patients</span>
###xml 743 750 <span type="species:ncbi:9606">patient</span>
###xml 964 971 <span type="species:ncbi:9606">patient</span>
###xml 1051 1059 <span type="species:ncbi:9606">patients</span>
The novel mutation at codon 188 in patient A (T188R) was found by routine sequencing of CJD suspects in the German surveillance [5], [23]. However, due to the negative family history and the absence of a genetic analysis of family members there is no evidence for the disease-causing effect of this mutation. No autopsy was performed. During clinical examinations CJD was strongly suspected because of the CJD-specific findings in EEG and CSF. The pathological VEP is common in CJD, even in patients without clinically affected visual system [39]. The MRI pattern was not typical as proposed for the CJD criteria because of the missing hyperintensity of the BG, even 12 months after onset, similar to three of four T188K mutations. Clinically patient A is similar to sporadic MM1/MV1 cases, because of the drastic visual problems. However, the disease duration (16 m.) exceeds the mean duration for this group (4-5 months). Homozygosity for V at codon 129 in this patient is remarkable since visual symptoms are very unusual in (sporadic) VV1 and VV2 patients. Dementia and ataxia in the course of the disease are common, ataxia is more typical of VV2. The PSWCs in EEG and the age at onset are similar to the sporadic VV2 subgroup, whereas the disease duration is at the outer limit for VV2.
###end p 57
###begin p 58
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PRNP</italic>
###xml 570 574 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Schatzl1">[40]</xref>
###xml 576 580 576 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Windl4">[41]</xref>
###xml 1075 1079 1075 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002147-Lorenz1">[42]</xref>
Similar to all novel point mutations whose causative nature is not supported by a genetic linkage study, the question arises whether mutation T188K is truly pathogenic and not merely a polymorphism accidentally occurring in cases of sCJD. However, there are several arguments strongly supporting the pathogenic role of this mutation: (1) It was not identified in 735 healthy controls. (2) Threonine at codon 188 of PRNP is highly conserved throughout all mammalians, indicating that this mutation is likely to have a dramatic effect on the function of the prion protein [40], [41]. Codon 188 is situated in the C-terminal half of the second alpha-helix, a firmly structured part of the protein, and a drastic exchange like the substitution of threonine for a highly basic amino acid such as arginine (T188R) or lysine (T188K) would result in a structural destabilization. (3) Cell culture experiments are strongly suggestive of a pathogenic role for this mutation, since increased proteinase K (PK) resistance and insolubility in non-denaturing detergents have been observed [42].
###end p 58
###begin p 59
The data presented here argue in favor of T188K being a pathogenic mutation causing genetic CJD. Since one individual with this mutation is now 79 years old and shows no signs of disease, this mutation may be associated with a penetrance under 100%. Further observations will have to show whether T188R is a pathogenic mutation.
###end p 59
###begin p 60
We thank Dr. S. Markus and Dr. A. Steinbrecher for close collaboration. We thank Dr. M. Groschup and Dr. J. Grassi for providing the antibodies L42 and 12F10. We are very grateful to E. Staniszewski, H. Lettenbauer, A. Henn and G. Kwiatkowski for expert technical assistance in genetic analysis, performing the autopsy, histological processing and Western blot analysis.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
Molecular genetic studies of Creutzfeldt-Jakob disease.
###end article-title 62
###begin article-title 63
Prion diseases.
###end article-title 63
###begin article-title 64
Mutations in familial Creutzfeldt-Jakob disease and Gerstmann-Straussler-Scheinker's syndrome.
###end article-title 64
###begin article-title 65
Genetic prion disease: the EUROCJD experience.
###end article-title 65
###begin article-title 66
###xml 22 27 <span type="species:ncbi:9606">human</span>
Molecular genetics of human prion diseases in Germany.
###end article-title 66
###begin article-title 67
Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome.
###end article-title 67
###begin article-title 68
Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene.
###end article-title 68
###begin article-title 69
[Epidemiology and clinical symptomatology of Creutzfeldt-Jakob disease].
###end article-title 69
###begin article-title 70
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
###end article-title 70
###begin article-title 71
The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases.
###end article-title 71
###begin article-title 72
Sequence variation in intron of prion protein gene, crucial for complete diagnostic strategies.
###end article-title 72
###begin article-title 73
Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene.
###end article-title 73
###begin article-title 74
Significant association of a M129V independent polymorphism in the 5' UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study.
###end article-title 74
###begin article-title 75
KORA-gen-resource for population genetics, controls and a broad spectrum of disease phenotypes.
###end article-title 75
###begin article-title 76
KORA-a research platform for population based health research.
###end article-title 76
###begin article-title 77
Effects of different experimental conditions on the PrPSc core generated by protease digestion: Implications for strain typing and molecular classification of CJD.
###end article-title 77
###begin article-title 78
Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease.
###end article-title 78
###begin article-title 79
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human transmissible spongiform encephalopathies.
###end article-title 79
###begin article-title 80
A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V.
###end article-title 80
###begin article-title 81
Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease.
###end article-title 81
###begin article-title 82
###xml 31 38 <span type="species:ncbi:9606">patient</span>
Creutzfeldt-Jakob disease in a patient with an R208H mutation of the prion protein gene (PRNP) and a 17-kDa prion protein fragment.
###end article-title 82
###begin article-title 83
Association of an 11-12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases.
###end article-title 83
###begin article-title 84
Mutations of the prion protein gene phenotypic spectrum.
###end article-title 84
###begin article-title 85
###xml 43 51 <span type="species:ncbi:9606">patients</span>
High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes.
###end article-title 85
###begin article-title 86
Novel prion protein gene mutation in an octogenarian with Creutzfeldt-Jakob disease.
###end article-title 86
###begin article-title 87
###xml 31 36 <span type="species:ncbi:9606">human</span>
WHO manual for surveillance of human transmissible spongiform encephalopaties including variant Creutzfeldt-Jakob-disease.
###end article-title 87
###begin article-title 88
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects.
###end article-title 88
###begin article-title 89
Clinical features of Creutzfeldt-Jakob disease with V180I mutation.
###end article-title 89
###begin article-title 90
Diffusion-weighted MRI in two cases of familial Creutzfeldt-Jakob disease.
###end article-title 90
###begin article-title 91
Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD.
###end article-title 91
###begin article-title 92
Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type.
###end article-title 92
###begin article-title 93
MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement.
###end article-title 93
###begin article-title 94
Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis.
###end article-title 94
###begin article-title 95
Lateralized and focal clinical, EEG, and FLAIR MRI abnormalities in Creutzfeldt-Jakob disease.
###end article-title 95
###begin article-title 96
A new point mutation of the prion protein gene in Creutzfeldt-Jakob disease.
###end article-title 96
###begin article-title 97
Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene.
###end article-title 97
###begin article-title 98
The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation.
###end article-title 98
###begin article-title 99
Creutzfeldt-Jacob disease associated with the PRNP codon 200Lys mutation: an analysis of 45 families.
###end article-title 99
###begin article-title 100
[Visual evoked potentials in Creutzfeldt-Jakob disease].
###end article-title 100
###begin article-title 101
Prion protein gene variation among primates.
###end article-title 101
###begin article-title 102
A candidate marsupial PrP gene reveals two domains conserved in mammalian PrP proteins.
###end article-title 102
###begin article-title 103
Cellular phenotyping of secretory and nuclear prion proteins associated with inherited prion diseases.
###end article-title 103
###begin p 104
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 104
###begin p 105
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was supported by a grant from the Federal Ministry of Health (Bundesgesundheitsministerium) and the European Commission (TSELAB QLK 2- CT-2002-81523). Genotyping in this study was partially supported within the German National Genomic Research Network (01GS0166) by the Federal Ministry of Education and Research (BMBF). The KORA research platform (KORA, Cooperative Research in the Region of Augsburg) was initiated and financed by the GSF-National Research Centre for Environment and Health, which is funded by the German Federal Ministry of Education and Research and of the State of Bavaria.
###end p 105

